Using antibodies recognizing oxidized phosphatidylcholine, including adducts with proteins that do not exhibit an apoB enhanced level of oxLDL, was reported in patients with coronary artery disease (Ehara et al., 2001). Here, APOB is linked to coronary artery disorder.